10x Genomics, Inc.
NASDAQ:TXGMedical - Healthcare Information Services
+$2.49 today
- Market cap
- $6.93B
- Beta
- 2.11
- P/E (TTM)
- -196.0
- EPS (TTM)
- -$0.18
Volume 2.10M
Average 3.06M
TXG Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
10x Genomics, Inc.NASDAQ: TXG
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses turns negative
Q3 FY2026 other income / expenses was -$2.42M, compared with $4.04M a year earlier. Trailing-twelve-month other income / expenses was $7.04M. Over 3 fiscal years it compounded at +128.2% a year.
Context
- Other income / expenses amounted to 11.0% of revenue in FY2025, up 8.3 pp from a year earlier.
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$2.42M or moves back toward the trailing-twelve-month quarterly average of $1.76M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 70.98M USD
- Year-over-year change
- +321.0%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.98M | +321.0% |
| FY2024 | 2024-12-31 | 16.86M | +1.8% |
| FY2023 | 2023-12-31 | 16.57M | +177.3% |
| FY2022 | 2022-12-31 | 5.97M | +844.8% |
| FY2021 | 2021-12-31 | (802K) | — |
Other Income / Expenses vs competitors
How TXG compares with its peers on the latest reported figures
- TXG's LTM Sep 2026 other income / expenses of $7.04M is the 5th highest of the 9 companies compared; the peer median is -$237.5K.
- Its year-over-year change of -61.3% is the 5th highest of 9, against a peer median of -67.1%.
- Other income / expenses amounts to 1.1% of revenue for TXG, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $115.4M | -49.1% | — | 4.5% | |
| LTM Jun 2026 | $73M | +55.3% | — | 1.6% | |
| LTM Jul 2026 | $19M | +138.0% | — | 0.3% | |
| LTM Sep 2026 | $8.85M | -85.1% | -13.5% | 1.9% | |
| LTM Sep 2026 | $7.04M | -61.3% | +128.2% | 1.1% | |
| LTM Mar 2026 | -$9.32M | -198.2% | — | 10.8% | |
| LTM Sep 2026 | -$13.45M | -269.3% | — | 1.1% | |
| LTM Jun 2026 | -$70.26M | -447.3% | — | 3.3% | |
| LTM Jul 2026 | -$98.08M | -19.7% | — | 3.4% | |
| Peer median (excluding TXG) | -$237.5K | -67.1% | -13.5% | 2.6% | |
Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 490.49M | 516.41M | 618.73M | 610.79M | 642.82M |
| Cost of Revenue | 74.09M | 120.39M | 209.41M | 196.3M | 198.94M |
| Gross Profit | 416.4M | 396.02M | 409.31M | 414.48M | 443.88M |
| Gross Margin | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% |
| Research & Development | 211.75M | 265.67M | 270.33M | 264.7M | 238.63M |
| Selling, General & Admin | 257.56M | 298.3M | 343.33M | 344.34M | 316.13M |
| Operating Expenses | 469.31M | 563.97M | 674.64M | 609.04M | 554.77M |
| Depreciation & Amortization | 28.25M | 33.01M | 43.62M | 43.71M | 43.82M |
| EBITDA | (24.6M) | (128.49M) | (205.11M) | (133.99M) | 3.91M |
| EBITDA Margin | -5.0% | -24.9% | -33.2% | -21.9% | 0.6% |
| Operating Income | (52.91M) | (167.94M) | (265.33M) | (194.56M) | (110.89M) |
| Operating Margin | -10.8% | -32.5% | -42.9% | -31.9% | -17.2% |
| Interest Income | 206K | 6.65M | 16.91M | 18.45M | 20.05M |
| Interest Expense | 866K | 476K | 33K | 4K | 0 |
| Other Income / Expenses | (802K) | 5.97M | 16.57M | 16.86M | 70.98M |
| Income Before Tax | (53.72M) | (161.97M) | (248.76M) | (177.7M) | (39.91M) |
| Pre-Tax Margin | -11.0% | -31.4% | -40.2% | -29.1% | -6.2% |
| Income Tax Expense | 4.51M | 4.03M | 6.34M | 4.93M | 3.64M |
| Net Income | (58.22M) | (166M) | (255.1M) | (182.63M) | (43.54M) |
| Net Margin | -11.9% | -32.1% | -41.2% | -29.9% | -6.8% |
| EPS (Basic) | (0.53) | (1.46) | (2.18) | (1.52) | (0.35) |
| EPS (Diluted) | (0.53) | (1.46) | (2.18) | (1.52) | (0.35) |
| Weighted Avg Shares | 110.35M | 113.86M | 117.17M | 120.45M | 124.75M |
| Weighted Avg Shares (Diluted) | 110.35M | 113.86M | 117.17M | 120.45M | 124.75M |
10x Genomics, Inc.
NASDAQ:TXG
Intrinsic Alpha fair value
Locked
Current Price
$57.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.